<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83924">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01840449</url>
  </required_header>
  <id_info>
    <org_study_id>A-94-52030-240</org_study_id>
    <nct_id>NCT01840449</nct_id>
  </id_info>
  <brief_title>Somatuline Predictive Factors in Acromegaly and NET</brief_title>
  <acronym>SOPRANo</acronym>
  <official_title>Non-interventional, Observational Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel® (ATG) Treatment in Subjects With Either Acromegaly or Neuroendocrine Tumours (NET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to identify predictive factors for the response to Lanreotide
      treatment in Acromegaly as well as in Neuroendocrine Tumours.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change in biochemical markers (Growth Hormone [GH] &amp; Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in biochemical markers (Growth Hormone [GH] &amp; Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Acromegaly</condition>
  <condition>Neuroendocrine Tumours</condition>
  <arm_group>
    <arm_group_label>Neuroendocrine Tumours</arm_group_label>
    <description>The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acromegaly</arm_group_label>
    <description>The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatuline Autogel® 60, 90 or 120 mg</intervention_name>
    <arm_group_label>Neuroendocrine Tumours</arm_group_label>
    <arm_group_label>Acromegaly</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Clinics and private practitioners who treat acromegaly and/or NET subjects with Somatuline
        Autogel® 60, 90 or 120 mg.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent (also mandatory in case of retrospective documentation of
             subject data)

          -  Diagnosis of acromegaly or NET with the intention to be treated with ATG or already
             on treatment with ATG

        Exclusion Criteria:

          -  The subject has already been included in this study

          -  Participation in an interventional trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Hoffmanns, MD, PhD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ipsen Recruitment Enquiries</last_name>
    <email>clinical.trials@ipsen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ENDOC</name>
      <address>
        <city>Hamburg</city>
        <zip>20357</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>April 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acromegaly</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Lanreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
